life-extension
AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer
AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit